Market Overview

Morgan Stanley Maintains on Allscripts Healthcare Solutions

Share:
Related MDRX
Allscripts Expands Patient Admin System, Signs Two new PAS Clients
13F Watch: Krevlin's Glenhill Advisors Buys Pier 1, Nexstar; Slashes American Airlines, Jamba

In a report published Wednesday, Morgan Stanley analyst Julie Murphy maintained an Overweight rating on Allscripts Healthcare Solutions (NASDAQ: MDRX), raising its price target to $20.00 from $17.00.

According to the report, following the previous Morgan Stanley note “What a Difference a Year Makes! Turnaround Thesis Validated” published this morning, analysts are updating model estimates and price target for MDRX.

“Our PT is based on a 2.7x EV/Sales multiple, the 2-yr avg FY1 multiple for MDRX pre-April 2012 (prior to the strategic alternatives upheaval seen that year) applied to our base case 2015 revenue est of $1,523M,” the report noted. “Our bull case valuation of $23 reflects a 2.9x EV/Sales multiple (3-yr avg multiple pre-April 2012) applied to our bull case 2015 revenue estimate of $1607M. Our bear case valuation of $14 is based on a 2.0x multiple (3-yr avg multiple) applied to our bear case 2015 revenue estimate of $1,471M.”

MDRX closed Tuesday at $15.52 with shares trading up at 2.51 percent.

Latest Ratings for MDRX

DateFirmActionFromTo
Jun 2015OppenheimerInitiates Coverage onPerform
Apr 2015Piper JaffrayUpgradesUnderweightNeutral
Apr 2015Stifel NicolausInitiates Coverage onHold

View More Analyst Ratings for MDRX
View the Latest Analyst Ratings

Posted-In: Julie Murphy Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (MDRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters